Quarterly Reporting: Investor Reality Check Or Pharma Communication Gap?
Executive Summary
Multi-billion dollar gaps exist between what investors think a company is worth one day and what they think the next. A Scrip analysis shows that these information gaps between big pharma and their shareholders are very common and are often bridged only by the mandatory quarterly reporting from companies. While unbalanced optimism or pessimism from investors might account for some of the chasm in understanding, an absence of interim guidance from companies is also a factor.
You may also be interested in...
Stock Scan November 2017: Generics get volatile
Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.